$CLNN

Clene Inc (CLNN) plans to submit an FDA application for its ALS drug CNM-Au8 in Q4, aiming for a mid-2027 decision. CEO Etherington cited survival benefits and neurofilament light changes as supporting data. The company has held five FDA meetings and completed financing to support the filing. If approved, CNM-Au8 could address thousands of patients annually, with Clene working on insurer and payer agreements.

Clene Inc. (CLNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 CLENE ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING ● Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders ● $4 million registered dire

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

Clene Inc. (CLNN) announced a $4M direct offering of 1.22M shares at $3.28 each, expected to close on September 17, 2026. The company plans to use the funds for corporate purposes, including regulatory activities and CNM-Au8 development. CLNN stock closed at $3.28 on Monday, down 8.12%, and is up 11.71% in pre-market trading.

Clene (CLNN) plans to submit an NDA for its ALS drug in Q4, following FDA-requested biomarker analyses. The company reported consistent neurofilament reductions across trials and believes its data links biomarker changes to clinical benefits. Clene aims for an FDA decision by year-end and a potential commercialization decision by early 2027.

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene expects to submit a New Drug Application for CNM-Au8 ® in ALS under the accelerated approval pathway in early fourth quarter of 2026 ● Clene announces survival and functional

Chidozie Ugwumba has reported a 9.7% beneficial ownership stake in Clene Inc. (CLNN), totaling 1,351,071 shares. This includes both issued common stock and shares issuable upon the exercise of immediately exercisable Tranche A, Tranche B, and Common Stock Purchase Warrants. The filing is an amendment to a Schedule 13G and references 12,778,307 shares outstanding as of May 14, 2026, as per Clene Inc.'s Form 10-Q.

SymBiosis II LLC, an entity associated with major Clene (NASDAQ: CLNN) shareholder Ugwumba Chidozie, reported selling a total of 78,679 shares of Clene Inc. common stock in two open-market transactions. These sales occurred on May 1, 2026, for 5,795 shares at $6.01, and on May 4, 2026, for 72,884 shares at $6.80. Following these transactions, SymBiosis II LLC indirectly holds 198,890 shares of Clene Inc.

A 10% owner of Clene (NASDAQ: CLNN), through the associated entity SymBiosis II, LLC, sold 19,497 shares of common stock in open-market transactions over three days in late April 2026. The sales were executed at prices ranging from $5.63 to $6.08 per share. Following these transactions, SymBiosis II, LLC still indirectly holds 277,569 shares of Clene Common Stock.

A Form 144 filing indicates that Symbiosis II LLC has reported multiple proposed and executed sales of Common Stock in Clene Inc. (NASDAQ: CLNN) during January–March 2026. The filing details numerous open-market dispositions, including 31,297 shares sold on March 31, 2026, for $152,316.52 and 32,705 shares sold on January 12, 2026, for $179,867.17, with individual trade sizes and cash amounts provided for each transaction. This filing provides transparency into Symbiosis II LLC's recent trading activities in CLNN shares.